Prevalent vertebral fracture is dominantly associated with spinal microstructural deterioration rather than bone mineral density in patients with type 2 diabetes mellitus

Masahiro Yamamoto*, Mika Yamauchi*, Toshitsugu Sugimoto*

Internal Medicine 1, Shimane University Faculty of Medicine, Izumo, Shimane, Japan

* These authors contributed equally to this work.
* masa-ya@med.shimae-u.ac.jp

Abstract

Background
An assessment of bone strength based on bone mineral density (BMD) underestimates the risk of fracture in patients with diabetes mellitus (T2DM). However, using the trabecular bone score (TBS) for estimating bone microarchitecture, previous studies showed that bone fragility is associated with deterioration of the microstructure concomitantly with decreased BMD. This study was conducted to clarify which of these skeletal-related factors had a more prominent relationship with bone fragility.

Research design and methods
A retrospective cross-sectional study was performed at Shimane University Hospital. A total of 548 Japanese patients with T2DM [257 postmenopausal women and 291 men aged over 50 years] were included. TBS of the spine was computed from dual-energy X-ray absorptiometry images obtained from BMD measurements.

Results
Vertebral fractures (VFs) were identified in 74 (28.8%) women and 115 (39.5%) men. A relationship between BMD and VFs was observed in the limited subgroup of women with a BMD T-score ≤-1.0. According to multivariate logistic regression analysis, low TBS was significantly correlated with prevalent VFs, independent of BMD in both genders, except for men with a BMD T-score > -1.0. The decision tree showed that the priority factor for determining VFs was TBS, not BMD.

Conclusion
Spinal microarchitecture represented by TBS was a more dominant skeletal factor for bone fragility than the decrease in bone mass, independent of BMD, in patients with T2DM.
replicate our study findings in their entirety, on reasonable request. Please contact Clinical Research Support Office, Shimane University Hospital, at kenkyu@med.shimane-u.ac.jp for all data requests.

**Funding:** This work was supported by Grants-in-Aid for Scientific Research (C) Grant No. 25460900 (to MY) from Japan Society for the Promotion of Science (JSPS) (https://www.jsp.s.go.jp/english/index.html) and Asahi Kasei Pharma Corporation and Eli Lilly Japan K.K. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** This work was supported by Grants-in-Aid for Scientific Research (C) Grant No. 25460900 (to MY) from Japan Society for the Promotion of Science (JSPS) (https://www.jsp.s.go.jp/english/index.html) and Asahi Kasei Pharma Corporation and Eli Lilly Japan K.K. The authors have declared that no competing interests exist including any employment and personal financial interests such as consultancy, patents, products in development, and marketed products. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

observation suggests that loss of structural bone quality was crucial underlying pathogenesis for bone brittleness in these populations, regardless of gender. An integrated assessment of bone strength by BMD and TBS would help diagnose diabetic osteoporosis.

---

**Introduction**

Vertebral fractures (VFs) are a common osteoporotic adverse event and are often asymptomatic [1]. According to two meta-analyses, patients with type 2 diabetes mellitus (T2DM) have a 1.38- and 1.7-fold higher risk of hip fracture than do nondiabetic subjects [2, 3], suggesting that patients with T2DM have an increased risk of fracture. Considering the evidence that VFs are an important sign for the risk of new VFs and nonvertebral fracture in nondiabetic subjects [4, 5], the assessment of bone fragility by prevalent VFs might be useful for the estimation of fracture risk in these patients. However, standard criteria for osteoporosis in patients with T2DM have not been established.

Measurements of bone mineral density (BMD) are the gold standard for evaluating bone strength in patients with primary osteoporosis [6]. However, assessments of bone quantity based on BMD underestimate the risk of fracture in patients with T2DM [2, 7, 8], suggesting that bone fragility in patients with T2DM is caused by poor bone quality [9]. The trabecular bone score (TBS), as computed from conventional BMD images of the lumbar spine captured using dual-energy X-ray absorptiometry (DXA), provides a texture index of spinal trabecular bone that is not captured by standard BMD measurements. Compared with nondiabetic subjects, patients with T2DM of both genders have significantly lower TBS [10–14], except in one study [15]. However, these studies did not provide information on the relationships between TBS and fracture risk. A few reports have identified an association between decreased TBS and an increased risk of fracture, including VFs, in patients with T2DM [15, 16] and populations with diabetes caused by various etiologies, including type 1 DM and steroid treatment [17]. However, these studies were performed in a diabetic population in which fractured patients had a significantly lower BMD than did nonfractured patients [15, 16, 18]. These studies demonstrated that standard BMD measurement can detect bone fragility [15, 17, 18]. These observations raised a question regarding what benefits are provided by measurement of TBS under the condition that BMD can detect bone fragility because these studies have not determined which pathological condition, the loss of bone mass or degeneration of the bone microarchitecture, is a more critical contributor to bone fragility in patients with T2DM.

Recently, the algorithm for evaluating fracture risk in patients with T2DM proposed by the Bone and Diabetes Working Group of the International Osteoporosis Foundation stated that a BMD T-score < -2.0 is the cutoff for starting osteoporosis treatment in patients with diabetes because that value is equivalent to nondiabetes at T-score < −2.5 [19]. In addition, surveillance of bone fragility in these patients is recommended for BMD and TBS. However, this algorithm does not indicate the role of TBS in diagnosing bone fragility in patients with T2DM.

A decision tree analysis is a major data mining method that mathematically builds tree-like classification or regression models by selecting the best relevant factor for predicting the incidence of a target outcome from among various factors. These analyses have been used in the management of public health care and determination of prognostic factors in various diseases [20, 21]. Thus, this evaluation may be useful for revealing which skeletal indices of bone mass or bone microarchitecture primarily affect bone fragility.

To elucidate the impacts of a decreased quantity of bone mass and a deteriorated quality of the bone structure on bone strength, we investigated the association between TBS and the...
presence of VFs in groups stratified by a BMD T-score = -1.0, which is a cutoff between normal bone and osteopenia, to observe the influence of BMD. In addition, decision tree analysis was performed with factors related to VFs obtained in the present study to determine which bone properties predominantly contributed to increased bone fragility.

**Subjects and methods**

**Subjects**

Five hundred forty-eight Japanese patients with T2DM [257 postmenopausal women (age range 45–89 years) and 291 men (age range 50–88 years)] who were referred to Shimane University Hospital from community clinics for diabetes treatment and who underwent BMD measurements were consecutively enrolled between 1 April 1998 and 31 December 2013. Their hemoglobin A1c (HbA1c) levels were higher than 6.2% upon enrollment. Patients were excluded if they had higher than normal serum creatinine levels (normal range for women, 0.44–0.83 mg/dL; men, 0.56–1.23 mg/dL); abnormal calcium metabolism, such as primary hyperparathyroidism; a medical checkup history indicating positivity for a glutamic acid decarboxylase antibody; or a history of falls or traffic accidents to eliminate the possibility of injury-associated fractures. The onset of T2DM was defined as the first incident of glucosuria or hyperglycemia. None of the patients were taking any bone-specific drugs or hormones that affected their bone metabolism, including sex steroids, glucocorticoids, warfarin, bisphosphonates, pioglitazone, glucagon-like peptide-1 (GLP-1) agonists, or sodium-glucose cotransporter-2 inhibitors. This study was approved by the Shimane University Institutional Committee on Ethics, a regional ethics board at Shimane University (IRB No. 1427). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was a retrospective evaluation of routine clinical data. For this type of research, formal consent is not required.

**Biochemical measurements**

Serum hemoglobin A1c (HbA1c) was determined by high-performance liquid chromatography. Fasting plasma glucose (FPG), creatinine (Cr), calcium, and phosphate levels were measured in fasting blood samples by using automated techniques at the central laboratory of our hospital as follows: the hexokinase method, enzymatic method, Arsenazo-III method, and enzymatic method. Serum bone-specific alkaline phosphatase (BAP) and urinary N-telopeptide (uNTX) levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA).

**Assessment of fractures**

In all subjects, lateral X-ray films of the thoracic and lumbar spine were obtained one month before and after the BMD assessment to identify a grade 1 or greater deformity of vertebrae as VFs according to Genant’s semiquantitative assessment [22]. These diagnoses were performed by two independent investigators who were blinded to the other’s readings. If the investigators did not agree on the presence of VFs, the X-ray film was independently reassessed. If the reevaluated findings still differed, that case was regarded as no fracture.

**Densitometry**

The anteroposterior BMD values of the lumbar spine were measured by DXA using a QDR-4500 system, which was replaced by a Discovery system on 1 October 2008 (Hologic, Waltham, MA, USA). The coefficient of variation for measurements of spinal BMD was 1.0%.
TBS
Calculations of TBS of the lumbar spine were performed using TBS iNsight software (Version 2.0.0, Med-Imaps, Bordeaux, France), as previously reported (13), with the anteroposterior L1–L4 BMD image (DXA image) obtained from bone densitometry.

Statistical analysis
All data are presented as the mean ± SD for each index. Mann-Whitney U tests were used to compare the parameters between subjects with and without VFs because these values were not always normally distributed by the Kolmogorov-Smirnov test. Categorical variables were compared using chi-square tests. Logistic regression analyses were performed to determine whether BMD or TBS was associated with VFs independent of the confounding factors that significantly correlated with VFs. Statistical analyses were performed using SPSS software (version 19; IBM Corporation, Tokyo, Japan), except for the decision tree analyses, which were performed using R version 3.4.1 (R Foundation for Statistical Computing) with the classification and regression tree (CART) package. The cutoff values of this analysis were mathematically determined by the CART package based on the Gini coefficient. The Gini coefficient ranges from 0, indicating perfect equality (where each two groups have 50% people with fractures), to 1, perfect inequality (where one group has all people with fracture and the other has people with no fractures). The CART program calculates the Gini coefficient for all variables applied to this package and then chooses the highest Gini coefficient. This Gini coefficient provides the highest performance cutoff value of a certain variable that divides one group into a fracture group and a nonfracture group at the node. P values less than 0.05 were considered statistically significant.

Results
Characteristics of the study population
The baseline characteristics of the subjects are shown in Table 1. Seventy-four women (28.8%) and 115 men (39.5%) had VFs. HbA1c levels and the duration of T2DM were 9.52 ± 2.09% and 12.6 ± 9.8 years in women and 9.31 ± 2.22% and 12.6 ± 9.7 years in men, respectively. The TBS was 1.236 ± 0.101 in women and 1.322 ± 0.085 in men.

Comparison of various parameters between patients with and without VFs among all participants
Compared with patients without VFs, patients of both genders with VFs were significantly older (P < 0.01) and had a significantly lower TBS (P < 0.01) (Tables 2 and 3). Only women with VFs presented significantly lower spinal BMD and T-scores than did women without VFs (P < 0.05). Significantly lower serum phosphate levels (P < 0.05) and a significantly longer duration of T2DM (P < 0.05) were observed in women with VFs than in women without VFs.

Comparison of various parameters between patients with and without VFs in the subgroup stratified by a spinal BMD T-score of -1.0
Participants were divided into subgroups based on a BMD T-score of -1.0 to exclude the effect of the BMD on the association between the TBS and the presence of VFs (Tables 2 and 3). A significantly lower TBS was recorded for patients of both genders in the VF group than for patients in the non-VF group regardless of the T-score subgroups. In contrast, a significantly lower BMD was observed only in women with VFs in BMD T-score ≤ -1.0. Patients in the VF
group were significantly older than those in the non-VF group, except among men with a T-score \( \leq -1.0 \). In the subgroup with a BMD T-score > -1.0, the duration of T2DM in women with fracture was significantly higher than that in those without fracture. The serum phosphate level in men with fracture was significantly lower than that in those without fracture.

**Association between the presence of VFs and BMD or TBS**

To clarify the association between bone fragility and bone-related indices, such as the BMD or TBS, we performed logistic regression analyses to investigate the relationships between the presence of VFs, an indicator of bone fragility, and BMD as well as TBS. In women, BMD was significantly correlated with the presence of VFs in the crude model in the group composed of all subjects and the subgroup with a BMD T-score \( \leq -1.0 \) (Fig 1). However, this significant association disappeared after adjustment for the confounding factors for VFs revealed by Tables 1 and 2, such as age, the duration of T2DM, and phosphate levels (Model 1). However, a significant relationship between the BMD and the presence of VFs was not observed in any men (Fig 2). In addition, these findings were unaffected by an additional adjustment for the hypoglycemic agent (data not shown).

In contrast to BMD, a low TBS was significantly and consistently correlated with an increased risk of the presence of VFs in the crude estimation and Model 1 in both genders in any group (Figs 1 and 2), except for men with a BMD T-score > -1.0 (Fig 2). In addition, these significant relationships were observed after additional adjustment for BMD (Model 2).
Decision tree analysis for the determination of the prevalence of VFs in patients with T2DM

The decision trees were constructed to determine the crucial factors for the incidence of VFs in descending order with all variables listed in Table 1, including the confounding factors shown in Fig 1: age, duration of T2DM, phosphate level, TBS, and T-score instead of BMD (Fig 3). At each level of bifurcation point in the tree-like chart, the best splitter to determine the presence of VFs was placed by a mathematical technique. The number of subjects and patients with VFs were described in each node or terminal. TBS was the top priority factor that differentiated female patients with VFs from those without VFs and was superior to BMD. In male patients, TBS was selected as the third factor for determination of the presence of VFs following age and creatinine levels.

The objective groups were classified into two subgroups based on the cutoff values of the given factors that minimized the variation in the fracture rate. The number of subjects and patients with VFs was described in each node or terminal.

Discussion

For the first time, the present study demonstrated that TBS was more definitive than BMD in discriminating patients with the presence of VFs by decision tree analysis. This observation...
was validated by the findings that the consistent and significant relationships between lower TBS and the presence of VFs were independent of BMD in both genders, except for men with a T-score > -1.0.

This study showed that TBS was chosen prior to BMD as an upper node of the decision trees for the prevalence of VFs in both genders. Decision trees, which are an essential component to establishing artificial intelligence (AI), such as the random forest approach, have been widely applied to computational biology and bioinformatics because of their usefulness in aggregating diverse types of data to make accurate predictions. Decision trees inform us which variables more profoundly contribute to the outcomes than others because tree-shaped charts were built by preferentially selecting the most relevant variables that are associated with target outcome. Currently, which bone component, bone mass and microarchitectures, has more critical impacts on bone fragility in patients with T2DM is unclear because previous studies did not validate the confounding effect of BMD on fracture risk [15, 16, 18]. However, for the first time, the present observations obtained by decision tree analyses indicated that lower TBS was a more powerful determining factor of bone fragility than the decrease in BMD in patients with T2DM.

Compared with decision tree analyses, logistic regression analyses were useful to determine the causes of bone fragility in this population. The assessment of bone fragility using the full range of BMD did not reflect the bone strength of the patients with T2DM, similar to previous studies [2, 7, 8]. In addition, bone strength in patients with T2DM is estimated at equivalent to

| Table 3. Comparison of various parameters between patients with T2DM presenting with and without vertebral fractures in men. |
|---------------------------------------------------------------|
| All subjects | BMD T-score ≤ -1.0 | BMD T-score > -1.0 |
|---------------------------------------------------------------|
| **Factors** | **Vertebral fractures** | **Vertebral fractures** | **Vertebral fractures** |
|---------------------------------------------------------------|
| **No** | **Yes** | **No** | **Yes** | **No** | **Yes** |
|---------------------------------------------------------------|
| No. of subjects | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
|----------------------------------------------------------------|
| Age (years) | 63.7 (8.7) | 67.9 (8.8) ** | 63.5 (9.2) | 67.3 (9.9) | 63.8 (8.5) | 68.1 (8.3) ** |
| BMI (kg/m²) | 23.5 (3.6) | 23.5 (3.3) | 23.1 (3.3) | 22.9 (3.9) | 24.0 (3.7) | 23.9 (3.1) |
| FPG (mg/dL) | 176.6 (61.9) | 164.8 (58.2) | 185.2 (66.4) | 168.6 (61.0) | 173.2 (59.9) | 163.5 (57.6) |
| HbA1c (%) | 9.50 (2.38) | 9.00 (1.90) | 9.33 (2.40) | 9.11 (1.93) | 9.57 (2.38) | 8.97 (1.91) |
| Duration of diabetes (years) | 12.7 (9.8) | 12.5 (9.5) | 10.5 (9.7) | 13.4 (10.8) | 13.6 (9.7) | 12.2 (8.9) |
| Creatinine (mg/dL) | 0.77 (0.16) | 0.76 (0.14) | 0.74 (0.17) | 0.74 (0.15) | 0.78 (0.15) | 0.77 (0.14) |
| Calcium (mg/dL) | 9.2 (0.3) | 9.2 (0.4) | 9.2 (0.3) | 9.2 (0.3) | 9.3 (0.4) | 9.2 (0.4) |
| Phosphate (mg/dL) | 3.4 (0.4) | 3.3 (0.5) | 3.4 (0.4) | 3.5 (0.5) | 3.3 (0.4) | 3.2 (0.5) * |
| BAP (U/L) | 27.7 (10.6) | 27.9 (9.7) | 27.3 (11.1) | 29.0 (11.8) | 27.8 (10.4) | 27.4 (8.6) |
| uNTX (nmol BCE/ mmol Cr) | 33.5 (17.3) | 34.1 (17.7) | 36.9 (16.2) | 39.1 (18.0) | 32.0 (17.6) | 32.1 (17.3) |
| T-score | 1.053 (0.215) | 1.055 (0.237) | 0.830 (0.072) | 0.805 (0.095) | 1.146 (0.184) | 1.162 (0.19) |
| Trabecular bone score | 0.04 (1.80) | 0.08 (1.97) | -1.82 (0.61) | -2.04 (0.80) | 0.82 (1.53) | 0.99 (1.61) |
| Use of Metformin | 38 [21.6%] | 20 [17.4%] | 3 [5.9%] | 5 [14.7%] | 35 [28.2%] | 15 [18.5%] |
| Use of sulfonylurea | 62 [35.2%] | 40 [34.8%] | 16 [30.8] | 10 [29.4%] | 46 [37.0%] | 30 [37.0%] |
| Use of Insulin | 35 [19.9%] | 23 [20.0%] | 10 [16.2%] | 8 [23.5%] | 25 [20.2%] | 15 [28.5%] |

**Mann-Whitney U tests:**

* P < 0.05 and
** P < 0.01, compared with each non-VF group

T2DM, type 2 diabetes; VF, vertebral fracture; BMI, body mass index; FPG, fasting plasma glucose; BAP, bone-specific alkaline phosphatase; uNTX, urinary levels of N-telopeptide; BCE, bone collagen equivalents.

https://doi.org/10.1371/journal.pone.0222571.t003

PLOS ONE | https://doi.org/10.1371/journal.pone.022571 September 16, 2019 7 / 13
bone fragility whose T-score is approximately 0.5 units lower than that in women without diabetes [7]. In contrast, TBS was significantly and consistently associated with the presence of
VFs in women. In addition, a similar finding was obtained in men with a BMD T-score ≤ -1.0 for the first time. These relationships were independent of BMD as shown in a previous report [17], suggesting that TBS might be an index reflecting structural bone quality, such as deterioration of the trabecular microarchitecture. Additionally, one recent study demonstrated that TBS possesses a nature sensitive to multiple risk factors for fracture, including the presence of diabetes [23]. Thus, TBS, not BMD, was robustly associated with the presence of VFs in patients with T2DM, supporting the results obtained from the decision trees in this study. These findings indicated that deterioration of bone microarchitecture, one component of bone quality, was a more dominant skeletal cause of bone fragility than the decrease in bone mass in patients with T2DM.

Here, the relationship between the presence of VFs and lower BMD was observed in limited subgroups, such as women with a BMD T-score ≤ -1.0, a threshold value for osteopenia, even though bone fragility is not easily determined by BMD in the typical population of patients with T2DM. As the BMD T-score increased, the trends of the hip fracture risk in patients with T2DM decreased [7], indicating that the risks of fracture in patients with T2DM are affected by BMD. However, those decreased fracture risks equal the risk of the population without T2DM [7], suggesting that the elevated relative risk of fracture in patients with T2DM compared to that in controls cannot always be explained by BMD, especially in the patients with T2DM whose BMD is within the normal range. In addition, meta-analysis showed that individuals with T2DM have higher BMD levels than do controls [24], suggesting that BMD in a...
typical T2DM population might be distributed in a higher range, which is not commonly con-
sidered to be the cause of fracture. Taking into consideration the results obtained from the
present study, logistic regression analyses confirmed that evaluation of fracture risk by BMD
was slightly useful in patients with T2DM, supporting the result demonstrated by the decision
tree analyses that BMD was not the best factor for determining the presence of VFs.

This study has some limitations. First, this study was not conducted with a sufficient num-
ber of population-based subjects to draw definitive conclusions. Second, the patients enrolled
in this study might have had relatively severe cases of T2DM and might not be representative
of typical Japanese patients with T2DM, as the diabetic conditions of the patients who attended
Shimane University Hospital, a tertiary care center, were considered to be more severe than
those of other patients with T2DM. Third, T2DM is a complex disease concomitant with vari-
ous metabolic disorders, and some of these disorders affect bone metabolism. This study could
not provide background data affecting osteoporosis, such as serum levels of vitamin D and
parathyroid hormone (PTH) and diabetes-related risk factors for fractures, such as advanced
glycation end-products (AGEs) [25, 26], endogenous secretory receptors for AGEs (esRAGE)
[27], and sclerostin [28, 29], on the relationship between TBS and VFs. Fourth, the patients
with osteoarthritis and lumbar scoliosis, which confound DXA measurements, were not
excluded. A study revealed that the severity of spine osteoarthritis did not correlate with TBS
in contrast to BMD [30]. Thus, the study protocol with easy clinical use, as in this study, was
potentially biased toward the diminishing ability to determine bone strength by BMD. Fifth,
this study did not consider the influence of the heterogeneous distribution of BMD or TBS
inside the vertebral body on bone strength. A recent study, which was not performed with sub-
jects with diabetes, indicated that subregional areal BMD reflects variations in “real” trabecular
bone microstructure that were better determined by high-resolution peripheral quantitative
computed tomography (CT) than by subregional TBS [31]. Thus, BMD in certain local areas
has the potential to be a helpful indicator of bone fragility in diabetic conditions. Sixth, infor-
mation on the cross calibration of TBS is not available. Finally, this study did not investigate
the effects of other T-scores, such as -2.5 or -2.0, which are the cutoff values for osteoporosis
determined by BMD [32] and the proposed value for starting osteoporosis treatment in
patients with T2DM [19], on the relationship between TBS and the presence of VFs because
the number of subgroups was too small to perform logistic regression analyses. For the same
reason, the limited sample size might have an effect on the results of women with a T-score
>-1.0 obtained from the logistic regression analysis because of the small sample size (n = 23).

In conclusion, the decision tree analyses revealed that spinal microarchitecture represented
by TBS was a more dominant skeletal factor for bone fragility than the decrease in bone mass,
independent of BMD, in patients with T2DM. In contrast, BMD measurement might be useful
in women or in the limited BMD range, such as osteopenia or osteoporosis. These observa-
tions suggest that loss of structural bone quality was a crucial underlying pathogenesis for
bone brittleness in these populations, regardless of gender. An integrated assessment of bone
strength by BMD and TBS would help diagnose diabetic osteoporosis.

Author Contributions

Conceptualization: Masahiro Yamamoto.
Data curation: Masahiro Yamamoto.
Formal analysis: Masahiro Yamamoto.
Funding acquisition: Masahiro Yamamoto.
Investigation: Masahiro Yamamoto.
Methodology: Masahiro Yamamoto.
Project administration: Masahiro Yamamoto.
Resources: Masahiro Yamamoto.
Software: Masahiro Yamamoto.
Validation: Masahiro Yamamoto.
Visualization: Masahiro Yamamoto.
Writing – original draft: Masahiro Yamamoto.
Writing – review & editing: Masahiro Yamamoto, Mika Yamauchi, Toshitsugu Sugimoto.

References

1. Fink HA, Milavetz DL, Palermo L, Nevitt MC, Cauley JA, Genant HK, et al. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res. 2005; 20(7):1216–22. Epub 2005/06/09. https://doi.org/10.1359/JBMR.050314 PMID: 15940375.

2. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007; 18(4):247–44. https://doi.org/10.1007/s00198-006-0253-4 PMID: 17068657.

3. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. American journal of epidemiology. 2007; 166(5):495–505. https://doi.org/10.1093/aje/kvm106 PMID: 1757306.

4. Gallagher JC, Genant HK, Crans GG, Vargas SJ, Kreege JH. Teriparatide reduces the fracture risk associated with increased number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2005; 90(3):1583–7. https://doi.org/10.1210/jc.2004-0826 PMID: 15613428.

5. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003; 33(4):522–32. Epub 2003/10/14. https://doi.org/10.1016/s8756-3282(03)00241-2 PMID: 14555255.

6. anonymous. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7–29, 2000: highlights of the conference. South Med J. 2001; 94(6):569–73. PMID: 11440324.

7. Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011; 305(21):2184–92. Epub 2011/06/03. https://doi.org/10.1001/jama.2011.715 PMID: 21632482; PubMed Central PMCID: PMC3287389.

8. Yamamoto M, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fracture independent of BMD or diabetic complications. J Bone Miner Res. 2009; 24(4):702–9. Epub 2008/12/04. https://doi.org/10.1359/jbmr.081207 PMID: 19049338.

9. Yamamoto M. Insights into bone fragility in diabetes: the crucial role of bone quality on skeletal strength. Endocr J. 2015; 62(4):299–308. Epub 2015/03/24. https://doi.org/10.1507/endocrj.EJ15-0129 PMID: 25797364.

10. Dhaliwal R, Cibula D, Ghosh C, Weinstock RS, Moses AM. Bone quality assessment in type 2 diabetes mellitus. Osteoporos Int. 2014; 25(7):1969–73. Epub 2014/04/11. https://doi.org/10.1007/s00198-014-2704-7 PMID: 24718377.

11. Kim JH, Choi HJ, Ku EJ, Kim KM, Kim SW, Cho NH, et al. Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab. 2015; 100(2):475–82. https://doi.org/10.1210/jc.2014-2047 PMID: 25368976.

12. Bonaccurso G, Filia E, Messina C, Maietti E, Ulivieri FM, Caudarella R, et al. Comparison of trabecular bone score and hip structural analysis with FRAX((R)) in postmenopausal women with type 2 diabetes mellitus. Aging Clin Exp Res. 2017; 29(5):951–7. https://doi.org/10.1007/s40520-016-0634-2 PMID: 27722900.

13. Xue Y, Baker AL, Nader S, Orlander P, Sanchez AJ, Kellam J, et al. Lumbar Spine Trabecular Bone Score (TBS) Reflects Diminished Bone Quality in Patients With Diabetes Mellitus and Oral Glucocorticoid Therapy. J Clin Densitom. 2017. https://doi.org/10.1016/j.jocd.2017.09.003 PMID: 29102474.
14. Baleanu F, Bergmann P, Hambye AS, Dekelver C, Iconaru L, Cappelle SI, et al. Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus: A study from the FRISBEE cohort. Int J Clin Pract. 2019; 73(5):e13347. https://doi.org/10.1111/ijcp.13347 PMID: 30912212.

15. Zhukouskaya VV, Eller-Vainicher C, Gaudio A, Privitera F, Cairoli E, Ulivieri FM, et al. The utility of lumbar spine trabecular bone score and femoral neck bone mineral density for identifying asymptomatic vertebral fractures in well-compensated type 2 diabetic patients. Osteoporos Int. 2016; 27(1):49–56. https://doi.org/10.1007/s00198-015-3212-0 PMID: 26138582.

16. Choi YJ, Ock SY, Chung YS. Trabecular Bone Score (TBS) and TBS-Adjusted Fracture Risk Assessment Tool are Potential Supplementary Tools for the Discrimination of Morphometric Vertebral Fractures in Postmenopausal Women With Type 2 Diabetes. J Clin Densitom. 2016; 19(4):507–14. https://doi.org/10.1016/j.jocd.2016.04.001 PMID: 27130256.

17. Leslie WD, Aubry-Roizier B, Lamy O, Hans D, Manitoba Bone Density P. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab. 2013; 98(2):602–9. Epub 2013/01/24. https://doi.org/10.1210/jc.2012-3118 PMID: 23941489.

18. Chen FP, Kuo SF, Lin YC, Fan CM, Chen JF. Status of bone strength and factors associated with vertebral fracture in postmenopausal women with type 2 diabetes. Menopause. 2019; 26(2):182–8. https://doi.org/10.1097/GME.0000000000001185 PMID: 30130285.

19. Ferrari SL, Abrahamson B, Napoli N, Akesson K, Chandra M, Eastell R, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int. 2018; 29(12):2585–96. https://doi.org/10.1007/s00198-018-4650-2 PMID: 30066131; PubMed Central PMCID: PMC667152.

20. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatology research: the official journal of the Japan Society of Hepatology. 2010; 40(4):251–60. https://doi.org/10.1111/j.1872-034X.2009.00607.x PMID: 20070391.

21. Kershaw TS, Lewis J, Westdahl C, Wang YF, Rising SS, Massey Z, et al. Using clinical classification trees to identify individuals at risk of STDs during pregnancy. Perspect Sex Reprod Health. 2007; 39(3):141–8. https://doi.org/10.1363/3914107 PMID: 17845525; PubMed Central PMCID: PMC2276881.

22. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8(9):1137–48. https://doi.org/10.1002/jbmr.5650080915 PMID: 8237484.

23. Martineau P, Leslie WD, Johansson H, Harvey NC, McCloskey EV, Hans D, et al. In which patients does lumbar spine trabecular bone score (TBS) have the largest effect? Bone. 2018; 113:161–8. https://doi.org/10.1016/j.bone.2018.05.026 PMID: 29882962; PubMed Central PMCID: PMCPMC6013036.

24. Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012; 27(5):319–32. Epub 2012/03/28. https://doi.org/10.1007/s10654-012-9674-x PMID: 22451239; PubMed Central PMCID: PMC374119.

25. Yamamoto M, Yamauchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93(3):1013–9. Epub 2007/12/28. https://doi.org/10.1210/jc.2007-1270 PMID: 18160470.

26. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94(7):2380–6. Epub 2009/04/23. https://doi.org/10.1210/jc.2008-2498 PMID: 19383780; PubMed Central PMCID: PMC2708944.

27. Yamamoto M, Yamauchi T, Yamauchi M, Sugimoto T. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care. 2009; 32(12):2263–8. Epub 2009/09/16. https://doi.org/10.2337/dc09-0801 PMID: 19752174; PubMed Central PMCID: PMC2782988.

28. Heilmeyer U, Carpenter DR, Patsch JM, Hamisch R, Joseph GB, Burghardt AJ, et al. Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures. Osteoporos Int. 2015; 25(4):1283–93. https://doi.org/10.1007/s00198-014-2988-7 PMID: 25582311.

29. Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013; 98(10):4030–7. Epub 2013/07/31. https://doi.org/10.1210/jc.2013-2143 PMID: 23894157.
30. Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res. 2014; 29(3):518–30. https://doi.org/10.1002/jbmr.2176 PMID: 24443324.

31. Vom Scheidt A, Grisolia Seifert EF, Pokrant C, Puschel K, Amling M, Busse B, et al. Subregional areal bone mineral density (aBMD) is a better predictor of heterogeneity in trabecular microstructure of vertebrae in young and aged women than subregional trabecular bone score (TBS). Bone. 2019; 122:156–65. https://doi.org/10.1016/j.bone.2019.02.014 PMID: 30776500.

32. Anonymous. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993; 94(6):646–50. https://doi.org/10.1016/0002-9343(93)90218-e PMID: 8506892.